
GI CANCERS
Latest News
Latest Videos

CME Content
More News

During a live event, Hagen Kennecke, MD, discussed key trials shaping the treatment landscape of PNETs.

FDA grants tentative approval to PNT2003, a Lutathera radioequivalent PRRT for SSTR+ GEP-NETs, paving way for wider access by 2026.

FDA confirms first-line BRAF V600E mCRC gains: encorafenib plus cetuximab with FOLFOX or FOLFIRI improves PFS and OS.

FDA fast-tracks PLT012, a CD36 metabolic checkpoint antibody for liver cancer, as phase 1 trial tests safety and early efficacy.

Phase 3 BREAKWATER finds encorafenib+cetuximab+FOLFIRI improves PFS and response in first-line BRAF V600E metastatic colorectal cancer.

During a live event, Hagen Kennecke, MD, discusses how RADIANT-4 and NETTER trials have reshaped NET care with everolimus and PRRT.

FDA grants orphan drug designation to HCB101 for gastric cancer; early trials suggest safer CD47 checkpoint blockade with promising tumor control in advanced settings.

Nivolumab–ipilimumab extends survival in unresectable HCC, but US cost-effectiveness falls short; dosing changes or price cuts may shift value.

FDA approves Optune Pax, a wearable tumor treating fields device, to pair with GnP chemo in locally advanced pancreatic cancer, extending survival and delaying pain.

FDA fast-tracks irpagratinib for FGF19+ advanced liver cancer, with early trials showing strong response rates and ongoing combo study momentum.

Final MOUNTAINEER data show tucatinib plus trastuzumab delivers durable responses and manageable safety in HER2+ RAS wild-type metastatic colorectal cancer.

Interim DURIPANC data suggest rintatolimod plus durvalumab may extend survival and boost immune activity in post‑FOLFIRINOX metastatic pancreatic cancer.

Phase 3 interim data show anbenitamab plus chemo boosts survival and response in previously treated HER2-positive gastric cancer with manageable toxicity.

Dr. Mukherjee explores the future of antibody-drug conjugates in GI cancers, emphasizing precision medicine and targeted therapies for optimal patient outcomes.

FDA fast-tracks pelareorep with bevacizumab and FOLFIRI for KRAS-mutant MSS metastatic colorectal cancer, after standout response and survival signals.

Clinicians explore the shift towards earlier use of antibody-drug conjugates in GI oncology, aiming to enhance patient outcomes and treatment efficacy.

FDA reviews new drug applications for rivoceranib and camrelizumab as first-line treatments for advanced liver cancer, promising improved survival rates.

Explore the vital role of antibody-drug conjugates in precision oncology for GI malignancies, focusing on managing payload-dependent toxicities effectively.

Discover the latest advancements in pancreatic cancer treatment, including targeted therapies and next-generation sequencing, transforming patient care and outcomes.

FDA reviews zanzalintinib and atezolizumab for metastatic colorectal cancer, offering hope for patients with limited treatment options.

Discover how antibody-drug conjugates (ADCs) are transforming treatment strategies for gastrointestinal cancers, enhancing precision and patient outcomes.

Lirafugratinib shows promise as a second-line treatment for cholangiocarcinoma, achieving significant response rates and durable outcomes in clinical trials.

New trial data show onvansertib enhances treatment response and progression-free survival in RAS-mutated metastatic colorectal cancer, paving the way for future therapies.

Dr. Filippo Pietrantonio explores the manageable safety profile of amivantamab combined with chemotherapy for metastatic colorectal cancer patients.

A novel neoadjuvant therapy combining PD-1 blockade and chemoradiotherapy shows promising results in treating patients with advanced rectal cancer with high Immunoscores.


































